درباره این اپیزود
You lose 30 pounds on a GLP-1. How much of it is muscle? On Episode 65, Klaudia Balogh and Don Moxley take on the objection nearly everyone lands on — "it eats muscle" — and find that it's wrong, but not entirely wrong.
Don calls this class of drugs one of the most important developments in medicine, arguably more important to the human race than AI. He also takes them himself, watches his HRV drop when he does, and has decided not to stay on them forever.
Both of those things can be true at once. In this episode, Klaudia and Don work through what's real about lean mass loss, what the pipeline looks like now, and the story that reframes the whole conversation: elementary schoolers being prescribed Wegovy.
In this episode:
- Why "GLP-1s eat muscle" is the wrong framing, and what's happening instead. You cannot lose weight without losing some lean mass, whether that's from a GLP-1, from fasting, or from bariatric surgery
- Roughly a quarter of the total weight lost on GLP-1 receptor agonists is lean mass, comparable to other weight-loss methods but significant for anyone already vulnerable to sarcopenia.
- The highest-risk profile for muscle loss: older adults, rapid or large absolute weight loss, low dietary protein, sedentary patterns, chronic kidney disease, or long-standing diabetes
- Why GLP-1 use and the fasting literature overlap more than either camp acknowledges, and what that means for training in a deficit
- Don's case that GLP-1s will matter more to the human race than AI, and why he thinks the risk-to-benefit profile is better than almost anything else in the medicine cabinet
- Reported findings that people move less after starting a GLP-1 — not dramatically less, but in a direction worth watching• Myostatin inhibition and the uncomfortable question of what happens when the muscle problem also gets a pharmaceutical answer
- Doctors are prescribing Wegovy to elementary-school-age children, well below the FDA's approved floor of 12. Off-label use in an age group where the safety data isn't established. Source: "When Diets Don't Work, Parents Turn to Wegovy for Elementary School Kids," The Wall Street Journal
- Where Klaudia and Don disagree on mic: he extends the benefit of the doubt to prescribing physicians, she keeps asking who's responsible for the education that has to come with the prescription.
Your 1% takeaway: if you're on a GLP-1 or considering one, two resistance sessions a week and protein-forward eating are the smallest evidence-backed hedge against the lean-mass tradeoff. And pick the movement you'd do anyway, because adherence is the whole game.
More from Klaudia: https://longevityjournalist.comMore from Don: https://trainrecoverwin.comActa Diabetologica review on muscle loss and GLP-1R agonists: https://pubmed.ncbi.nlm.nih.gov/41201615/
Who's the 90% Healthy Podcast for?
It’s for you who wants to build a resilient body without losing your mind. If you are sick of counting every calorie, tracking too many stats, or not even wanting to start, yet ready to stop feeling just “OK”. Klaudia and Don invite you to build resilient health that bends with real life. No rigid rules. No guilt. Just simple 1% shifts that create a strong foundation, so you can sleep like a baby, perform like a boss. and feel damn good. We cut through the noise, bring you real science (not TikTok trends), and make it easy to understand what works for the long run.
Tune in wherever you listen to your podcasts.
DISCLAIMER: This podcast is for informational and educational purposes only and is not medical advice. Nothing here replaces care from a qualified healthcare professional. Talk to your doctor before starting, stopping, or changing any medication, supplement, or exercise program. Hosts and guests share personal experience and opinion, and some discussion may involve off-label medication use. In an emergency, contact your local emergency services.
